Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 5/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21408418 | 1.00 | TBXAS1 (0.58) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL23120204 | 0.90 | TBXAS1 (0.50) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL9046908 | 0.88 | TBXAS1 (0.50) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL18079807 | 0.88 | TBXAS1 (0.50) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL21408447 | 0.87 | TBXAS1 (0.65) | TBXAS1TP53ALDH1A1CYP19A1PRKCI | |
| SCHEMBL8600458 | 0.85 | TBXAS1 (0.52) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL1709955 | 0.85 | TBXAS1 (0.53) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL8495419 | 0.84 | TBXAS1 (0.60) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL21408576 | 0.82 | TSHR (0.42) | TBXAS1TP53KDM4ETSHREGLN3 | |
| SCHEMBL28486016 | 0.82 | TSHR (0.42) | TBXAS1TP53KDM4ETSHREGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3775325-B1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-08-28 | — | — | EP | claimed |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2024-08-06 | — | — | US | claimed |
| EP-3775325-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-02-17 | — | — | EP | claimed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | claimed |
| WO-2019185468-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2019-10-03 | — | — | WO | claimed |
| EP-3775325-B1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2024-08-28 | — | — | EP | disclosed |
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | BASF SE (DE) | 2024-08-06 | — | — | US | disclosed |
| EP-3775325-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-02-17 | — | — | EP | disclosed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | disclosed |
| US-20210025070-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2021-01-28 | — | — | US | disclosed |
| WO-2019185468-A1 | COMPOSITION FOR TIN-SILVER ALLOY ELECTROPLATING COMPRISING A COMPLEXING AGENT | BASF SE (DE) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12054842-B2 | Composition for tin-silver alloy electroplating comprising a complexing agent | SCN11A, GRIA3, NR3C1 | TBXAS1 4028/4885TP53 2220/4885KDM4E 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.